Alzheimer's disease (AD) is a multigenic neurodegenerative disorder characterized by distinct neuropathological hallmarks including deposits of the β-amyloid (Aβ) peptide. A β is a 39-to 43-amino acid peptide derived from the proteolytic processing of the amyloid precursor protein (APP). While increasing evidence suggests that altered APP processing and Aβ metabolism is a common feature of AD, the relationship between the levels of A β and various APP products and the onset of AD remains unclear. We have undertaken a screen to characterize genetic factors that modify APP processing, A β metabolism and A β deposition in a genomic-based yeast artificial chromosome (YAC) transgenic mouse model of AD. A mutant human APP YAC transgene was transferred to three inbred mouse inbred strains. Despite similar levels of holo-APP expression in the congenic strains, the levels of APP C-terminal fragments as well as brain and plasma Aβ in young animals varied by genetic background.
INTRODUCTION
Alzheimer's disease (AD), the most common cause of dementia in the elderly, is characterized by distinct neuropathological hallmarks, including extracellular deposits of the amyloid β (Aβ) peptide (1) . Genetic studies demonstrate that AD is a heterogeneous, multigenic disorder with several distinct etiologies (2) including: dosage imbalance for chromosome 21 as occurs in Down syndrome (DS); mutations in the amyloid precursor protein (APP) gene on chromosome 21, the presenilin 1 (PS1) gene on chromosome 14 and the presenilin 2 (PS2) gene on chromosome 1 in early -onset FAD; and inheritance of distinct apolipoprotein E (ApoE) gene alleles on chromosomes 19 in late-onset FAD. Current data suggests that these four AD genes account for less than 30% of genetic risk for AD (2) . Recently, numerous studies have provided evidence that many of the genetic forms of AD share common pathogenic mechanisms that involve alterations in A β metabolism (3).
Aβ is a 39-to 43-amino acid peptide derived from the proteolyt ic processing of APP (4) .
APP, a type-I integral membrane protein, matures through the constitutive secretory pathway and is processed by several different proteases (5) . First, α-secretase cleavage of APP within the A β sequence generates a C-terminal fragment (CTFα) that prevents the formation of Aβ. A competing pathway results in β-secretase cleavage at the N -terminus of A β and generation of a separate C-terminal fragment (CTF β ) which is subsequently processed by γ-secretase to generate Aβ of either 40 (A β40) or 42 (Aβ42) amino acids in length. However, at present the exact relationship between the levels of A β and the various APP processing products and the deposition of Aβ remains poorly defined.
4
Our laboratory has initiated a screen to characterize genetic factors that modify APP processing, A β metabolism and Aβ deposition in a transgenic mouse model of AD. Previously, we generated and characterized the genomic-based APP transgenic mouse line R1. 40 , containing several copies of a yeast artificial chromosome (YAC) with the entire human APP gene harboring the Swedish FAD mutation (6) (7) (8) (9) ).
In the current manuscript, we generated mouse strains containing the R1.40 transgene in defined genetic backgrounds by repeated backcrossing to three inbred mouse strains. Despite similar levels of holo-APP expression in the three strains, the levels of brain APP CTFs as well as brain and plasma Aβ40 and Aβ42 in young animals varied depending upon genetic background. In addition, the congenic strains exhibited dramatic alterations in the age of onset of Aβ deposition. These studies demonstrate that Aβ metabolism and deposition are under genetic control in mice and that altered APP processing and Aβ metabolism in young animals may have implications for later development of AD-like neuropathology.
RESULTS

Generation of R1.40 Congenic Strains of Defined Genetic Background
We have focused on developing a genomic-based mouse model of AD, through the introduction of complete copies of human AD genes into the germline of mice (6) (7) (8) (9) (10) . Transgenic line R1. 40 contains the entire human APP gene carried on a YAC with the K670N/M671L mutation (6, 11) .
We have demonstrated that line R1.40 develops extracellular Aβ deposits and associated neuropathology that closely resembles those alterations observed in human AD (7) (8) (9) . In the process of analyzing patterns of Aβ deposition in R1.40 mice, we observed extensive variation 5 between transgenic animals at the same age (data not shown) indicating the presence of stochastic and/or genetic factors that impact A β deposition.
To characterize genetic modifiers of APP processing, Aβ metabolism, and A β deposition and neuropathology in mice, the R1.40 YAC transgene was transferred into three different genetic backgrounds by repeated backcrossing to the inbred mouse strains C57BL/6J, DBA/2J and 129S1/SvImJ and selection for the R1.40 transgene at each generation. The animals described in the current study were backcrossed to the tenth generation to C57BL/6J (abbreviated B6-R1.40, official designation B6.Cg-Tg(APP)R1.40Lmb), the tenth generation to DBA/2J (abbreviated D2-R1.40, official designation D2.Cg-Tg(APP)R1.40Lm) and the fifth generation to 129S1/SvImJ (abbreviated 129S1-R1.40, official designation 129S1.CgTg(APP)R1.40Lmb). On average, animals at the fifth generation backcross are 94% identical to the inbred line (termed incipient congenic), while animals at the tenth generation backcross are 99.8% identical to the inbred line (termed certified congenic) (12) . The integrity and copy number of the transgene in the three congenic strains was confirmed by Southern blotting (data not shown).
Analysis of holo-APP and APP CTFs
In initial experiments designed to examine the effect of genetic background on APP processing, brain extracts from hemizygous B6-R1.40, D2-R1.40 and 129S1-R1.40 transgenic mice were analyzed by Western blot analysis for various APP products. Steady-state levels of brain holo -APP and APP CTFs were determined at four weeks of age (Fig. 1) . No significant differences in the fold increase in total APP expression (mouse + human) over endogenous C57BL/6J App was observed in the three sets of samples, suggesting that the levels of brain holo-APP are approximately equal in the three congenic strains. By contrast, the relative steady-state levels of 6 the APP CTFs (8) , expressed as the ratio of CTF β / (CTF β +CTF α ) was significantly lower in the 129S1-R1.40 brain extracts compared to either the B6-R1.40 or D2-R1.40 extracts (Fig. 1) .
Analysis of (B6 x 129S1)F 1 -R1.40 brain extracts, revealed an indistinguishable CTF ratio when compared to the B6-R1.40 parental strain. These results suggest that the gene alleles responsible for the lower CTF ratio observed in the 129S1-R1.40 congenics are recessive to the "high" B6 alleles. On the other hand, analysis of the (D2 x 129S1)F 1 -R1.40 brain extracts revealed a CTF ratio indistinguishable from the 129S1 -R1.40 parental strain (Fig. 1) , suggesting that the alleles responsible for the lower CTF ratio observed in the 129S1-R1.40 congenics is dominant to the "high" DBA alleles. These data demonstrate that there is altered production and turnover of APP CTFs dependent upon genetic loci in the different mouse backgrounds.
Analysis of Aβ Metabolism
To further examine the effects of genetic background on APP processing, the levels of the two major isoforms of Aβ (A β40 and Aβ42) in brain extracts and plasma from four-week-old hemizygous B6-R1.40, D2-R1.40 and 129S1-R1.40 congenics were determined by ELISA.
Pairwise comparisons revealed B6-R1.40 animals with the highest levels of both brain and plasma A β40 and Aβ42, 129S1-R1.40 animals with intermediate levels and D2-R1.40 animals with the lowest levels (Fig. 2) . The statistically significant differences in steady-state levels of Aβ between D2-R1.40 and B6-R1.40 animals were maintained at both 21 and 60 days of age (Fig. 3) . Immunoprecipitation/mass spectrometry analysis of brain A β from the 129S1-R1.40, B6-R1.40 and D2-R1.40 congenics revealed no significant differences in the identity of the A β species produced (data not shown). These novel results suggest that the altered steady-state level of Aβ in young animals is under control of unique genetic loci in the R1.40 congenic strains.
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To gain further insight into genetic differences that result in high A β levels in the B6-R1.40 strain and low Aβ levels in the D2-R1.40 strain, four-week-old hemizygous (B6 x D2) F 1 -R1.40 and (B6 x D2)F 2 -R1.40 transgenic mice were generated and analyzed for the levels of brain Aβ40 and Aβ42 by ELISA (Fig. 4) . The levels of brain Aβ peptides in the (B6 x D2) F 1 s were not significantly different from the B6-R1.40 parental strain, but were significantly different from the D2-R1.40 parental strain. These results demonstrate that the gene alleles controlling the "high" levels of brain Aβ in young B6-R1.40 congenics are dominant over the "low" D2-R1.40 alleles. In addition, the levels of brain Aβ40 and Aβ42 in the F 2 population varied across both parental and F 1 Aβ values and were strongly correlated within the F 2 population (r=0.9, p<0.0001, 2-tailed Pearson test), suggesting that the same genetic factors regulate both Aβ peptides.
Finally, correlational analysis of steady state APP CTF ratios and Aβ levels on individual animals where both measurements were obtained (B6-R1.40, n=7; D2-R1.40, n=6; 129S1-R1.40, n=9) revealed no significant correlation between these two biochemical measurements (data not shown). This is consistent with our previous observations that revealed that steady state APP CTF ratios are not predictive for the levels of Aβ in different brains regions of R1.40 transgenic mice in a mixed B6-129S1 background or in different brain regions of Tg2576, a cDNA-based APP transgenic mouse model in a mixed B6-SJL background (8) .
Analysis of Aβ Deposition
To examine whether the altered steady-state levels of Aβ in young congenics is correlated with altered Aβ deposition later in life, aging studies of homozygous B6-R1.40, D2-R1.40 and (B6 x D2)F 1 -R1.40 animals were conducted. While no A β deposition was observed in any animals at five months of age (data not shown), all homozygous 13.5-month -old B6-R1.40 animals (n=4) exhibited Aβ deposition in parietal cortex (Fig. 5B ). By contrast, no A β deposition was observed in 13.5-month-old homozygous D2-R1.40 animals (n=3) (Fig. 5A ). 13.5 -month -old homozygous (B6 x D2)F 1 -R1.40 animals (n=3) also exhibited A β deposition in parietal cortex ( 
DISCUSSION
The generation of Aβ via the proteolytic processing of APP and its subsequent deposition into senile plaques is thought to be central to AD pathogenesis (3). However, the relationship between the levels of A β and the various APP processing products generated over the lifespan of humans and the onset of AD remains quite obscure. For example, the levels of Aβ measured in plasma or fibroblasts from human subjects do not consistently predict whether or when AD w ill 9 develop (13, 14) . In addition, the increase in Aβ secretion caused by individual FAD mutations does not necessarily correlate with age of onset within FAD pedigrees (15 -17) . This is likely due to numerous confounding environmental and genetic factors inherent in human population-based aging studies. Consistent with this hypothesis, considerable variation in the duration, severity, symptoms, age of onset and clinical/neuropathological correlations of AD has been observed in multiple studies (18-22). Notably, even within families containing the same early-onset FAD mutation, substantial variation in symptoms, age of onset, pathology, duration and penetrance is exhibited (23-25) suggesting the presence of modifier loci for A β metabolism and AD in these families. Given the difficulties in identifying the factors that modulate risk for developing AD in humans we have turned to the mouse as a genetically defined and tractable model system to gain insight into the relationship between A β metabolism and AD pathogenesis.
In the current studies we have focused on examining the effects of defined genetic backgrounds and environment on APP processing, Aβ metabolism and Aβ deposition in a transgenic mouse model of AD. We previously generated and characterized mouse line R1.40, a genomic-based APP transgenic model that exhibits numerous AD phenotypes (6) (7) (8) (9) (10) . In this report, using the R1.40 line in defined inbred mouse strains, we show that APP processing, Αβ metabolism and Aβ deposition are modified dependent upon genetic background in the mouse and that alterations in steady state levels of Aβ in young animals may impact the onset of Aβ deposition later in life. These congenic transgenic mouse strains now provide a unique resource to characterize gender-specific, environmental-specific as well as spatial and temporal alterations in APP processing, Aβ metabolism and Aβ deposition. In addition, the congenic strains will enable genetic mapping studies to identify genes responsible for alterations in both in vivo Aβ metabolism and Aβ deposition. represents an age of onset delay of at least 48% (6.5 months/13.5 months). If a lifespancorrected, proportional delay were observed in humans, the average age of onset of Aβ pathology would be delayed ~30 years, drastically reducing the rates of AD pathology observed in human populations (26, 27). Identification of the mouse genes responsible for the delay in Aβ deposition observed in these mouse strains may thus prove critical in efforts to identify factors that delay the age of onset of AD in human populations. Furthermore, these studies have important implications for the study of human AD in that the levels of Aβ in very young individuals may be correlated with the age of onset of AD pathology. This hypothesis will need to be examined in greater detail using a large population of animals in which the levels of plasma Aβ are measured in each animal at a variety of ages and correlated with A β deposition in the same animals at an older age. This type of longitudinal study in a large group of F 2 animals will help determine whether the genetic factors that regulate Aβ metabolism and Aβ deposition in these strain s are the same or different and thus provide insight into the relationship between the levels of Aβ throughout aging and eventual A β deposition.
This study also has profound implications for the study of the various transgenic mouse models of AD which are largely maintained on hybrid genetic backgrounds (28-32). Our data demonstrate that significant phenotypic alterations in Aβ metabolism and deposition are conferred by genetic background. Phenotypic variability due to genetic background has been suggested in other APP transgenic mouse models (33) (34) (35) but has yet to be formally addressed experimentally. For example, the PD-APP transgenic model of AD, which is derived from a hybrid background that includes the C56BL/6J and DBA/2J inbred strains examined here, exhibits extensive variability in A β deposition dependent upon the parent of origin of the transgene (35) . The results presented here suggest that interpretation of biochemical, pathological and behavioral data generated in the various transgenic models on mixed genetic backgrounds is likely to be substantially complicated by various genetic factors segregating uniquely in the progeny of these models. 
MATERIALS AND METHODS
Animals
R1.40 YAC transgenic animals were previously described (6) . Congenic strains were generated by consecutive backcrossing onto one of the following inbred strains (from The Jackson Laboratory, Bar Harbor, ME): B6 (stock number 000664), D2 (stock number 000671) and 129S1 (stock number 002448). Typically transgene positive males were crossed with inbred females, but at least one cross of transgene positive females with inbred males was made in each series to ensure the inclusion of the inbred Y chromosome. Transgene hemizygosity/homozygosity was determined by fluorescent in situ hybridization (37) and integrity of the transgene was and water ad libitum and were specific pathogen free.
Tissue Procurement
Plasma was obtained from the orbital sinus. Both plasma and brain tissue were immediately frozen after procurement on dry ice before storage at -80 o C. For neuropa thological analysis of older animals, brains were sagitally bisected with half of the brain frozen and half immersion fixed in 4% paraformaldehyde in phosphate buffered saline for immunohistochemistry.
Western Blot Analysis
Analysis of the steady-state levels of holo-APP and APP CTFs was performed on brain extracts from four-week-old hemizygous congenic strains and F 1 s as described previously (8) were fit to that line and a value for each sample was given relative to the standard curve of endogenous C57BL/6J App. All samples were analyzed in triplicate and an average determined.
Brain and Plasma Aβ40 and Aβ42 ELISA
For measurement of strain differences in levels of Aβ, frozen brain tissue was Dounce homogenized in 70% formic acid (150mg/ml) as previously described (38, 39) . Homogenates were spun at 100,000 x g for 1 hour and supernatants neutralized by 20x dilution in 1M Tris.
Homogenates were subjected to an ELISA with capture monoclonal antibody BNT77 (specific to Aβ 17-28) and monoclonal detection antibodies BA27 for Aβ40 and BC05 for Aβ42.
Comparison to a curve of standard peptides yielded the pmole Aβ/g of brain tissue and pM (for plasma) results reported. For determination of levels of Aβ40 at various ages, a commercially available ELISA was utilized (Biosource International, Camarillo, CA). Frozen brains were homogenized in 5M guanidine HCl/ 50 mM Tris (125mg/ml) using a Powergen homogenizer 
Immunoprecipitation/Mass Spectrometry
Immunoprecipitation/mass spectrometry analysis of Aβ peptides was performed as described (40) . Relative peak intensities of Aβ peptides to the internal standard were used for quantification.
Immunohistochemistry
Brains were embedded in paraffin and 10 µm brain sections were processed for immunohistochemistry as described (9). Monoclonal antibody 6E10 to A β 1-17 (Signet Laboratories, Dedham, MA) and the amyloid -specific dye Thioflavine-S were utilized to visualize Aβ deposits in brain sections.
Statistics
Comparisons between groups of animals were made using analysis of variance (ANOVA 
